Explainable AI for detection and characterization of stage B heart failure

Stage B heart failure represents a silent phase where the heart already shows structural or functional alterations, but the patient does not yet manifest symptoms. Identifying these individuals early is key to applying interventions that halt progression toward symptomatic disease. In this context, explainable artificial intelligence (XAI) emerges as a promising tool to detect and characterize this condition with greater transparency and fairness. However, current developments have significant limitations: most studies use methods such as SHAP, LIME, or saliency maps, but without systematically validating their explanations or considering differences by sex or ethnicity. Furthermore, the lack of external validation and inconsistency in model evaluation prevent their real clinical adoption. To overcome these barriers, a comprehensive approach combining robust models with rigorous interpretability is necessary. At this point, companies like Q2BSTUDIO can provide advanced technological solutions. For example, the development of AI for businesses allows creating customized artificial intelligence systems that not only predict risk but also explain their decisions in a way that is understandable for doctors and patients. Additionally, the creation of custom applications facilitates the integration of these models into real clinical workflows, respecting security and privacy requirements. The implementation of AI agents capable of analyzing multimodal data —such as electrocardiograms, echocardiograms, and biomarkers— can elevate diagnostic accuracy, while AWS and Azure cloud services ensure scalability and regulatory compliance. Equally relevant is the cybersecurity of health data, an aspect that Q2BSTUDIO addresses through pentesting protocols and audits. Likewise, business intelligence services based on Power BI allow visualizing population patterns and monitoring the effectiveness of interventions. In short, explainable artificial intelligence for stage B heart failure requires a complete technological ecosystem, where custom software and interdisciplinary collaboration are fundamental pillars to advance toward more predictive, personalized, and fair medicine.